Dear Colleague:

There are two new vaccine products we would like you to know about.

The meningococcal quadrivalent conjugate vaccine (MenACWY) vaccine formulation, MenQuadfi™ (Sanofi), is approved for use in individuals 2 years of age and older. The vaccine is administered as a single 0.5 mL intramuscular dose. Starting at 2 years of age, MenQuadfi is interchangeable with the other MenACWY vaccines, Menveo® (GSK) and Menactra® (Sanofi). For individuals younger than 2 years of age, Menveo can be used starting at 2 months of age and Menactra can be used starting at 9 months of age. The package insert for MenQuadfi is available here.

Also available for ordering is VAXELIS™ (Sanofi and Merck), the new hexavalent vaccine indicated for protection against diphtheria, tetanus, pertussis, polio, hepatitis B, and Haemophilus influenzae type B (Hib). This is the first vaccine available in the U.S. which has a hepatitis B and Hib component in addition to DTaP and polio components. The vaccine is approved for use as a three-dose series in children from 6 weeks through 4 years of age (prior to the 5th birthday). The three-dose series consists of a 0.5 mL intramuscular injection administered at 2, 4 and 6 months of age. For more information on VAXELIS, see the package insert.

Both of these vaccines are available through the New York City Vaccines for Children program (VFC) and can be ordered through the regular VFC ordering modules in the Citywide Immunization Registry (CIR).

These vaccines have new vaccine codes that will need to be used to ensure proper reporting of these vaccinations to CIR.

- DTaP, IPV, Hib Hep B (VAXELIS) – CVX code is146
- MenACWY TT conjugate (MenQuadfi) – CVX code is 203

For questions on any immunization-related issue, please call (347) 396-2400 or email nycimmunize@health.nyc.gov. We thank you for your continuing efforts at protecting NYC residents from vaccine-preventable illnesses.

Sincerely,

Jane R. Zucker, MD, MSc